Study | Year | Method of analysis | Nb of patients | FIGO stage | Macrometastatic SLN (%) | Micrometastatic SLN (%) |
---|---|---|---|---|---|---|
Lambaudie | 2003 | H&E +IHC | 12 | IA2-IB1 | 2 (18.2) | 0 |
Niikura | 2004 | H&E +IHC | 20 | IB1-IIA | 2 (10) | 0 |
Martinez Palones | 2004 | H&E +IHC | 23 | IA2-IIA | 3 (13) | 0 |
Kraft | 2006 | H&E +IHC | 54 | IB1-III | 21 (42) | na |
Total | Â | Â | 109 | Â | 28 (25.7) | Â |